Phacilitate Leaders World 

Advanced Therapies Investment Report

Advanced Therapies Investment Report

This report provides a comprehensive guide to successfully investing in advanced therapies. It also outlines across six chapters each of the challenges and opportunities of this sector for investors. Produced in partnership with Biotech and Money

The report is broken down into six chapters to cover the main risk factors and challenges of developing advanced therapies to guide you through this burgeoning industry and help to ensure you see a return on your investments. Here's an overview of the chapters:

  • Overview of the advanced therapy industry
  • Understanding cell and gene therapy pipelines
  • Building value for cell and gene therapies and establishing market access pathways
  • Manufacturing, commercial operations and supply chain
  • Understanding biopharma interest
  • Advice for investors

View the report here

Advanced therapies banner

 

 

 

Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK